UCT’s South African Tuberculosis Vaccine Initiative (SATVI) is once again the recipient of major tuberculosis (TB) research funding.

SATVI’s co-director, Professor Willem Hanekom(pictured below), was awarded a $5.3-million (R36-million) research grant by the Bill & Melinda Gates Foundation, specifically to learn why some persons exposed to the tuberculosis germ – Mycobacterium tuberculosis – develop TB, while others do not.

Worldwide nine million people develop TB annually, and 1.7 million die. Only 10% of people who are infected with the TB germ develop lung disease.

If successful, the research project can make a significant contribution to the fight against TB.

“Our first aim is to learn what to measure in blood to indicate that an exposed person will develop TB disease,” says Hanekom. “This will allow targeted intervention with antibiotics.

“The knowledge gained from our research should also guide development of new vaccines, to prevent TB altogether.”

This three-year project will bring together some of the world’s best scientists from Seattle, Stanford and San Diego in the US, and the Netherlands. The study will be led by Hanekom from UCT’s Faculty of Health Sciences.

The research team will analyse stored blood samples already collected from 6 363 adolescents. Nearly 50% of these adolescents were found to be infected with the TB germ at enrollment.

Some developed TB during two years of follow-up, but most remained healthy.

Stored blood will now be retrieved to look for differences in immune responses between those that developed TB and those who remained healthy. The researchers will use cutting edge technology for their search for these “correlates of risk of TB disease”.

Article by UCT

Facebook Comments


JOIN us now! 200 000+ student community get it monthly

Don't forget to stay in know. Students across the country join daily to ensure they never miss out. Drop your email in the box.

Your data and privacy is important to us. We strive to provide the utmost in transparency and always allow the opportunity to opt-out. Know your rights and visit our legal section